Core Viewpoint - Guizhou Bibet Pharmaceutical Co., Ltd. has announced the approval of a proposal to use its own funds to pay for fundraising project expenses, which will later be replaced by raised funds [1][5]. Fundraising Overview - The company completed its initial public offering (IPO) in 2025, issuing 90 million shares at a price of 17.78 yuan per share, raising a total of 1.6002 billion yuan, with a net amount of approximately 1.4911 billion yuan after deducting issuance costs [2]. Fundraising Project Details - The total investment for the three major fundraising projects amounts to 2.0046 billion yuan, with specific allocations as follows: - New drug research and development: 949.12 million yuan - Qingyuan R&D center and formulation industrialization base construction: 555.49 million yuan - Supplementing working capital: 500 million yuan [3]. Replacement Reason and Process - The core reason for using self-owned funds initially is due to restrictions on salary and tax payments during the implementation of fundraising projects. Payments for salaries, social insurance, and other related expenses must be made from the company's basic deposit accounts, not directly from the fundraising special account [3]. Operational Process - The finance department will monthly track the amounts paid with self-owned funds for the fundraising projects and will initiate replacement applications quarterly, following internal approval procedures [4]. Opinions and Impact Analysis - Independent directors believe the matter does not involve changes in the direction of fundraising and does not harm the interests of the company and shareholders. The supervisory board confirms that necessary approval procedures have been followed, which will enhance the efficiency of fundraising usage [5]. Company Impact - The operation strictly adheres to the principle of dedicated use of fundraising and will not change the direction of the funds. This approach will meet the actual needs for salary and tax payments and improve operational management efficiency. The approval of this proposal marks a substantial advancement in the fundraising projects, accelerating new drug development and construction of the R&D center [6].
必贝特拟以自有资金先行支付募投项目款项 14.91亿元募集资金将等额置换